» Articles » PMID: 31547431

Consensus-Derived Quality Performance Indicators for Neuroendocrine Tumour Care

Abstract

Quality performance indicators (QPIs) are used to monitor the delivery of cancer care. Neuroendocrine tumours (NETs) are a family of individually uncommon cancers that derive from neuroendocrine cells or their precursors, and can occur in most organs. There are currently no QPIs available for NETs and their heterogeneity makes QPI development difficult. CommNETs is a collaboration between NET clinicians, researchers and advocates in Canada, Australia and New Zealand. We created QPIs for NETs using a three-step consensus process. First, a multidisciplinary team used the nominal group technique to create candidates ( = 133) which were then curated into appropriateness statements (62 statements, 44 sub-statements). A two-stage modified RAND/UCLA Delphi consensus process was conducted: an online survey rated the statement appropriateness then the top-ranked statements ( = 20) were assessed in a face-to-face meeting. Finally, 10 QPIs met consensus criteria; documentation of primary site, proliferative index, differentiation, tumour board review, use of a structured pathology report, presence of distant metastasis, 5- and 10-year disease-free and overall survival. These NET QPIs will be trialed as a method to monitor and improve care for people with NETs and to facilitate international comparison.

Citing Articles

Clinical Management of Neuroendocrine Neoplasms in Clinical Practice: A Formal Consensus Exercise.

Bartolomei M, Berruti A, Falconi M, Fazio N, Ferone D, Lastoria S Cancers (Basel). 2022; 14(10).

PMID: 35626105 PMC: 9140035. DOI: 10.3390/cancers14102501.


Management of neuroendocrine neoplasms: conformity with guidelines in and outside a center of excellence.

Morin C, Benedetto K, Deville A, Milot L, Theillaumas A, Hervieu V Endocr Connect. 2022; 11(6).

PMID: 35521801 PMC: 9254288. DOI: 10.1530/EC-22-0097.

References
1.
Gagliardi A, Simunovic M, Langer B, Stern H, Brown A . Development of quality indicators for colorectal cancer surgery, using a 3-step modified Delphi approach. Can J Surg. 2006; 48(6):441-52. PMC: 3211732. View

2.
Howe J, Cardona K, Fraker D, Kebebew E, Untch B, Wang Y . The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society. Pancreas. 2017; 46(6):715-731. PMC: 5502737. DOI: 10.1097/MPA.0000000000000846. View

3.
Yao J, Hassan M, Phan A, Dagohoy C, Leary C, Mares J . One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26(18):3063-72. DOI: 10.1200/JCO.2007.15.4377. View

4.
Hallet J, Coburn N, Singh S, Beyfuss K, Koujanian S, Liu N . Access to care and outcomes for neuroendocrine tumours: does socioeconomic status matter?. Curr Oncol. 2018; 25(5):e356-e364. PMC: 6209547. DOI: 10.3747/co.35.3930. View

5.
Perren A, Couvelard A, Scoazec J, Costa F, Borbath I, Delle Fave G . ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic Stratification. Neuroendocrinology. 2017; 105(3):196-200. DOI: 10.1159/000457956. View